- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07438782
Eerste Studie bij Mensen (FTIH) om de Veiligheid en Voorlopige Activiteit van GSK5533524 Alleen of in Combinatie te Onderzoeken bij Volwassen Deelnemers met Gevorderde Solide Tumoren
Een fase 1, open-label, multicenterstudie van GSK5533524 alleen of in combinatie met andere antikankermiddelen, bij volwassen deelnemers met geselecteerde gevorderde solide tumoren
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.
Studie Overzicht
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Studie Contact Back-up
- Naam: EU GSK Clinical Trials Call Center
- Telefoonnummer: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Stephanie Lheureux
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- susie lau
-
Montreal, Quebec, Canada, H2X 0A9
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Diane Provencher
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
Capital Region
-
København Ø, Capital Region, Denemarken, 2100
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Lise Omland
-
-
-
-
-
Helsinki, Finland, 00029
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Katriina Jalkanen
-
-
-
-
-
Bordeaux, Frankrijk, 33076
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Coriolan Lebreton
-
Villejuif, Frankrijk, 94805
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Kaissa Ouali
-
-
-
-
-
Saitama, Japan, 350-1298
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Kosei Hasegawa
-
Shizuoka, Japan, 411-8777
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Akiko Furusawa
-
Tokyo, Japan, 104-0045
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Kan Yonemori
-
Tokyo, Japan, 135-8550
- Werving
- GSK Investigational Site
-
Hoofdonderzoeker:
- Shigehisa Kitano
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Elena Garralda Cabanas
-
Madrid, Spanje, 28009
- Werving
- GSK Investigational Site
-
Hoofdonderzoeker:
- Ana Oaknin
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Madrid, Spanje, 28027
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Antonio González Martín
-
Madrid, Spanje, 28041
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Ainhoa Madariaga Urrutia
-
Madrid, Spanje, 28050
- Werving
- GSK Investigational Site
-
Hoofdonderzoeker:
- Emiliano Calvo Aller
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Cambridge, Verenigd Koninkrijk, CB2 2QQ
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Joo Ern Ang
-
Edinburgh, Verenigd Koninkrijk, EH4 2XU
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Charlie Gourley
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107-4330
- Werving
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Hoofdonderzoeker:
- Ida Micaily
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
San Antonio, Texas, Verenigde Staten, 78229-3307
- Werving
- GSK Investigational Site
-
Hoofdonderzoeker:
- Drew Rasco
-
Contact:
- US GSK Clinical Trials Call Center
- Telefoonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Telefoonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Is at least 18 years of age or the legal age of consent
- Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory or intolerant to standard therapy, has exhausted all treatment options and is not considered a candidate for definitive radiotherapy.
- Has documented disease progression based on radiologic imaging, during or after most recent line of treatment.
- Has at least one target lesion per RECIST 1.1.
- Has an Eastern Cooperative Oncology Group performance status of 0 or 1 and no deterioration in the 2 weeks before enrollment.
- Has adequate organ function.
- Has a life expectancy of at least 3 months.
Exclusion Criteria:
- Has a history of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, congestive heart failure or clinically significant arrhythmia not controlled by Standard of care therapy.
- Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion.
- Has untreated brain or central nervous system metastases or metastases that have progressed
- Has a Grade ≥2 corneal epithelial condition.
- Has any active renal condition
- Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.
- Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy.
- Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or current ILD/pneumonitis.
- Has a lung-specific intercurrent clinically significant illness
- Has FEV1 <50% predicted
- Has chronic enteritis or inflammatory bowel disease or any history of clinically significant bleeding of gastrointestinal tract or clinically significant obstruction and/or perforation and/or fistulae of GI tract.
- Has a known hypersensitivity to any component of GSK5533524 or its excipients.
- Has history of severe allergies, or severe infusion related reactions, or idiosyncrasy to recombinant humanized proteins.
- Has received any cytotoxic chemotherapy drugs, or other anti-tumor drugs within 28 days prior to the first dose of study drug.
- Has received radiotherapy to the lungs, or to adjacent organs, within 6 months prior to the first dose of study intervention; locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study intervention.
- Has received immunosuppressive agents or required long-term glucocorticoid therapy within 30 days prior to first dose of study treatment.
- The use of concomitant medications known to prolong the QT/QTc interval or potentially cause torsades de pointes.
- Has corrected QT interval by Fridericia formula (QTcF) >470 msec or QTcF >480 msec for participants with bundle branch block.
- Has a left ventricular ejection fraction (LVEF) < 50%.
- Has risk factors for prolonged QT/QTc or TdP, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Deel 1b: GSK5533524 Dosisuitbreiding
|
GSK5533524 will be administered. |
|
Experimenteel: Part 1a: GSK5533524 Dose Escalation
|
GSK5533524 will be administered. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Deel 1a: Aantal deelnemers met dosisbeperkende toxiciteiten (DLT's) per dosisniveau
Tijdsspanne: Tot 21 dagen
|
Tot 21 dagen
|
|
|
Deel 1a: Aantal deelnemers met bijwerkingen (AEs), ernstige bijwerkingen (SAEs), naar ernst per dosisniveau
Tijdsspanne: Tot ongeveer 34 maanden
|
Tot ongeveer 34 maanden
|
|
|
Part 1b: Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 27 months
|
ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). |
Up to approximately 27 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Deel 1a & 1b: Aantal deelnemers met bijwerkingen (AEs), ernstige bijwerkingen (SAEs), behandeling-gerelateerde bijwerkingen (TEAEs) naar ernst, bijzonder belanghebbende bijwerkingen (AESIs), en bijwerkingen die leiden tot dosisaanpassingen en stopzetting van de behandeling
Tijdsspanne: Tot ongeveer 34 maanden
|
Tot ongeveer 34 maanden
|
|
|
Deel 1a & 1b: Farmacokinetische (PK) concentraties van GSK5533524 en zijn componenten
Tijdsspanne: Tot ongeveer 27 maanden
|
Tot ongeveer 27 maanden
|
|
|
Deel 1a & 1b: Aantal deelnemers met anti-medicijnantilichamen (ADA) tegen GSK5533524
Tijdsspanne: Tot ongeveer 27 maanden
|
Tot ongeveer 27 maanden
|
|
|
Deel 1a & 1b: Titers van ADA tegen GSK5533524
Tijdsspanne: Tot ongeveer 27 maanden
|
Tot ongeveer 27 maanden
|
|
|
Part 1a: Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 27 months
|
ORR is the proportion of participants with a BOR of CR or PR as assessed by the investigator according to RECIST 1.1. |
Up to approximately 27 months
|
|
Part 1a & 1b: Duration of Response (DoR)
Tijdsspanne: Up to approximately 27 months
|
DoR is evaluated in participants who achieve a CR or PR, based on investigator assessment per RECIST 1.1. |
Up to approximately 27 months
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 300163
- 2025-524165-25 (Andere identificatie: EU CT Number)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-tijdsbestek voor delen
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD-toegangscriteria voor delen
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .